08048035968
Erlocip 150 mg Good Quality Tablets to UK - Birmingham | Phoenix Exim | Trusted Exporter

1. General Information

Erlocip 150 mg is an anticancer tablet containing erlotinib. It works by blocking signals from the epidermal growth factor receptor (EGFR), a protein that can help cancer cells grow and multiply.

For appropriate NSCLC patients, EGFR mutation testing is important when determining whether erlotinib is suitable. FDA-approved companion diagnostic testing identifies relevant EGFR alterations such as exon 19 deletions and exon 21 L858R.

2. Product Information

  • Brand: Erlocip
  • Strength: 150 mg
  • Active ingredient: Erlotinib
  • Dosage form: Tablet
  • Drug class: EGFR tyrosine kinase inhibitor
  • Therapeutic category: Targeted anticancer medicine
  • Route: Oral

Erlotinib 150 mg is a commonly used dose in the treatment of appropriately selected NSCLC patients.

3. Uses of Erlocip 150 mg

Erlocip 150 mg may be prescribed for certain patients with:

  • EGFR-mutated non-small-cell lung cancer
  • Locally advanced or metastatic NSCLC in appropriate treatment settings
  • Certain cases of NSCLC following previous treatment, according to the treating oncologist's assessment

Erlotinib has also been used with gemcitabine for locally advanced, unresectable or metastatic pancreatic cancer, although the labeled pancreatic-cancer dose is 100 mg daily, not 150 mg.

4. Benefits of Erlocip 150 mg

When prescribed for a suitable patient, Erlocip may:

  • Target cancer cells carrying certain EGFR alterations
  • Help slow cancer-cell growth and multiplication
  • Help control disease progression
  • Provide a targeted treatment option for eligible NSCLC patients
  • Be administered orally rather than intravenously

The effectiveness of erlotinib depends strongly on the cancer type, molecular profile, previous treatments and individual patient factors.

5. Side Effects of Erlocip 150 mg

Possible side effects include:

  • Skin rash
  • Diarrhea
  • Loss of appetite
  • Fatigue
  • Nausea
  • Dry skin
  • Itching
  • Mouth inflammation
  • Eye irritation
  • Changes in liver-function tests

Clinical data for erlotinib 150 mg reported rash and diarrhea among the most common adverse reactions.

6. Common Side Effects

Commonly reported effects include:

  • Rash or acne-like skin eruption
  • Diarrhea
  • Tiredness
  • Reduced appetite
  • Nausea
  • Dry skin
  • Itching
  • Stomatitis
  • Eye irritation

The severity varies from patient to patient. Persistent or severe symptoms should be reported to the treating doctor.

7. How to Use Erlocip 150 mg

Take Erlocip exactly as prescribed by the oncologist.

For the NSCLC indication, the labeled erlotinib dose is 150 mg once daily on an empty stomach—at least 1 hour before or 2 hours after food.

Swallow the tablet as directed. Do not change the dose, stop treatment, or compensate for a missed dose without medical advice.

8. How Erlocip 150 mg Works

Erlocip contains erlotinib, which inhibits the EGFR tyrosine kinase. EGFR can transmit signals that promote cancer-cell growth and survival.

By blocking EGFR signaling, erlotinib can interfere with pathways involved in the growth and multiplication of susceptible cancer cells. Its benefit is greatest in appropriately selected tumors with relevant EGFR alterations.

9. Safety Advice

  • Use only under the supervision of an experienced cancer specialist.
  • EGFR testing may be required to determine whether erlotinib is appropriate for certain NSCLC patients.
  • Take the medicine on an empty stomach as directed.
  • Inform your doctor about all medicines and supplements you take.
  • Tell your doctor if you have liver problems.
  • Seek medical attention for severe or persistent diarrhea.
  • Report significant skin reactions.
  • Contact your doctor promptly for new or worsening breathing difficulties, as serious lung reactions can occur.
  • Report eye pain, severe irritation or vision changes.
  • Avoid self-medication or changing the dose.

Serious adverse reactions can include interstitial lung disease, severe liver toxicity, gastrointestinal perforation, serious skin reactions and serious corneal problems.

10. FAQs

Q1. What is Erlocip 150 mg?
Erlocip 150 mg is an erlotinib-containing targeted anticancer tablet used primarily for appropriately selected NSCLC patients.

Q2. What is the active ingredient?
The active ingredient is erlotinib 150 mg.

Q3. Is Erlocip 150 mg a chemotherapy medicine?
It is an oral targeted cancer therapy, specifically an EGFR tyrosine kinase inhibitor, rather than traditional cytotoxic chemotherapy.

Q4. How often is Erlocip 150 mg taken?
For the labeled NSCLC regimen, erlotinib 150 mg is taken once daily on an empty stomach.

Q5. Can Erlocip be taken with food?
The labeled NSCLC regimen specifies taking erlotinib at least 1 hour before or 2 hours after food.

Q6. Does every lung-cancer patient need Erlocip?
No. Suitability depends on the cancer diagnosis, EGFR status, disease stage, previous treatment and the oncologist's assessment.

Q7. Can Erlocip cause skin rash?
Yes. Skin rash is one of the commonly reported adverse reactions with erlotinib.

Q8. Should Erlocip be stopped if side effects occur?
Do not stop it independently. Contact the treating oncologist, who can determine whether treatment interruption or dose adjustment is necessary.

11. Substitute for Erlocip 150 mg

Possible erlotinib alternatives or other EGFR-targeted therapies may include medicines such as gefitinib or osimertinib, depending on the patient's specific EGFR alteration, treatment history and current clinical guidelines. These medicines are not automatically interchangeable with Erlocip.

For this reason, a substitute should be selected only by the treating oncologist rather than based solely on the same indication or strength. FDA companion-diagnostic information recognizes erlotinib, gefitinib and osimertinib for specific EGFR alterations in NSCLC.

12. SEO Keywords

  • Erlocip 150 mg Tablet
  • Erlocip 150 mg exporter
  • Erlocip 150 mg supplier India
  • Erlocip 150 mg medicine exporter
  • Erlocip 150 mg wholesale supplier
  • Erlotinib 150 mg Tablet
  • Erlotinib 150 mg exporter from India
  • Erlotinib 150 mg supplier
  • Erlotinib tablets exporter India
  • Erlocip 150 mg pharmaceutical exporter
  • Erlocip 150 mg oncology medicine supplier
  • Erlocip 150 mg cancer medicine exporter
  • Erlocip 150 mg supplier from Nagpur
  • Erlocip 150 mg exporter from Nagpur India
  • Phoenix Exim Erlocip 150 mg supplier
  • Phoenix Exim pharmaceutical exporter
  • cancer medicine exporter from India
  • oncology medicine exporter from Nagpur
  • EGFR targeted therapy supplier India
  • Erlotinib supplier to USA
  • Erlotinib supplier to UK
  • Erlotinib supplier to Australia
  • Erlotinib supplier to Singapore
  • Erlotinib supplier to Canada
  • Erlotinib supplier to South Korea
  • Erlotinib supplier to UAE
  • Erlocip 150 mg international pharmaceutical supplier
  • Erlotinib 150 mg B2B supplier India
  • Erlotinib 150 mg wholesale exporter
  • pharmaceutical export company Nagpur India
Aug 14th, 2026 3:07 PM

Keywords